There is currently no consensus on second-line therapies for ITP, which include medical therapies such as rituximab, thrombopoietin receptor agonists (TPO-RAs), and immunosuppressants, and surgical management with splenectomy [2]. Here, TPO is linked to autoimmune thrombocytopenic purpura.